We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Absinthe's Effects were Due to High Alcohol Content

By Labmedica staff writers
Posted on 07 May 2008
Absinthe--the exotic green aperitif--was believed to possess mind-altering effects and toxic side effects when consumed to excess. More...
A team of scientists from Europe and the United States has concluded that the culprit was the high alcohol content, rather than thujone, the compound widely believed responsible for absinthe's effects.

Although consumed diluted with water, absinthe contained about 70% alcohol, giving it a "140-proof wallop.” In late 19th-century, Paris bohemian artists and writers believed it expanded consciousness with psychedelic effects and called it "the Green Fairy” and "the Green Muse.” The drink's popularity spread through Europe and to the United States. However, illness and violent episodes among drinkers gave absinthe the reputation as a dangerous drug, and it was banned in Europe and elsewhere.

In a new study, Dirk W. Lachenmeier, Ph.D., from the Chemisches und Veterinäruntersuchungsamt (CVUA; Karlsruhe, Germany) and colleagues analyzed 13 samples of pre-ban absinthe from sealed bottles--"the first time that such a wide ranging analysis of absinthe from the pre-ban era has been attempted.” The study appeared online in the April 18, 2008 edition of the American Chemical Society's bi-weekly Journal of Agricultural and Food Chemistry.

The comprehensive chemical analysis included thujone, widely regarded as the "active” ingredient in absinthe. "It is certainly at the root of absinthe's reputation as being more drug than drink,” according to Dr. Lachenmeier. Thujone was blamed for "absinthe madness” and "absinthism,” a collection of symptoms including hallucinations, facial contractions, numbness, and dementia.

The researchers explained that scientists know very little about the composition of the original absinthe produced in France before that country banned the drink in 1915. Only a single study had previously analyzed one sample of preban absinthe.

However, the study by Dr. Lachenmeier found relatively small concentrations of thujone, amounts less than previously estimated and not sufficient to explain absinthism. Thujone levels in preban absinthe actually were about the same as those in modern absinthe, produced since 1988, when the European Union (EU) lifted its ban on absinthe production. Extensive laboratory tests found no other compound that could explain absinthe's effects.

"All things considered, nothing besides ethanol was found in the absinthes that was able to explain the syndrome of absinthism,” according to Dr. Lachenmeier. He added that scientific data could not explain preban absinthe's reputation as a psychedelic substance. Recent historic research on absinthism concluded that the condition probably was alcoholism.


Related Links:
Chemisches und Veterinäruntersuchungsamt

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Mammography System (Analog)
MAM VENUS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.